IDL Diagnostics AB (publ) (STO:IDLDX)

Market Cap	92.14M -12.3%
Revenue (ttm)	58.95M +7.6%
Net Income	-4.41M
EPS	-0.02
Shares Out	230.36M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	232,395
Open	0.4000
Previous Close	0.4040
Day's Range	0.3850 - 0.4000
52-Week Range	0.2500 - 0.5300
Beta	0.94
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 20, 2026

About IDL Diagnostics AB

IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden. It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever. Its vitro diagnostic biomarkers are used in breast, bladder, and prostate cancer therapies. The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2000
• Employees: 25
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IDLDX

Financial Performance

In 2025, IDL Diagnostics AB's revenue was 53.11 million, a decrease of -7.54% compared to the previous year's 57.44 million. Losses were -12.15 million, 264.0% more than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 10, 2026

Data Sources Report a data error